Benefits of Early MGUS Screening: Istopmm Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023

ASH 2023 | The iStopMM study: myeloma screeningПодробнее

iSTOPMM study and early MGUS and SMM screening | Joshua Richter, MD | ASH 2021Подробнее

Screening for Monoclonal Gammopathy of Undetermined Significance: First Results from iStopMM StudyПодробнее

Updates from the iStopMM studyПодробнее

Autoimmune Diseases Are Not Associated with MGUS: Results of the Population-Based iStopMMПодробнее

What is the IMF's iStopMM study? Early screening for myeloma: Advantages, impact, and benefitsПодробнее

MGUS with Multiple Paraproteins: Results from the Population-Based iStopMM Screening StudyПодробнее

MGUS and Thrombotic Events: Istopmm Study Results | Sæmundur Rögnvaldsson, MD, PhD | ASH 2023Подробнее

Hypercalcemia in Individuals with MGUS: Results from the iStopMM StudyПодробнее

iStopMM Scientific Discussion - Sæmundur RögnvaldssonПодробнее

An insight into the prevalence of various subtypes of MGUS in the iStopMM studyПодробнее

The risk of thrombotic events in patients with MGUS: an analysis from the iStopMM trialПодробнее

Update on the iStopMM Study | Sigurður Kristinsson, MD, PhD | IMS 2024Подробнее

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myelomaПодробнее

Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from iStopMMПодробнее

Addressing the benefits & potential drawbacks of early detection & intervention in the iStopMM studyПодробнее

iStopMM study – the impact of nationwide screeningПодробнее

iStopMM analysis results: autoimmune diseases are not associated with MGUSПодробнее